Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting
Editas Medicine presented new preclinical data for EDIT-401, showing a ≥90% mean LDL-C reduction across all dose groups in non-human primates. The LDL-C lowering was rapid and durable, lasting through ~6 months with no adverse clinical observations at the therapeutically relevant dose (1.5 mg/kg).
Key figures
- Drug Name
- EDIT-401
- Phase Of Trial
- preclinical
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.